Cadila Gets 5 Observations from USFDA for Subsidiary’s Injectables Facility

Cadila Healthcare said the US health regulator has issued five observations after inspection of its subsidiary Liva Pharmaceuticals’ injectables manufacturing facility. “This was a product specific pre-approval inspection. It concluded with 5 observations. Liva will respond to USFDA within 15 days. It may be noted that at present Liva does not export any products to the US market,” Cadila Healthcare said in a filing to BSE. The injectables facility is located at Vadodara. United States Food and Drug Administration (USFDA) conducted the inspection from August 20-28. Liva is a 100 percent subsidiary of Cadila Healthcare. – Business Standard